TrialClinical cancer research : an official journal of the American Association for Cancer Research2008

Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.

Fred R Hirsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.